Intro-to-MC
Intro-to-MC
Medical Cannabis
D AVID WOLF E , M.D., FA CR
A RT HRIT IS A N D RHE U MAT IS M
A S S OCIATES, P C
ME D ICA L CA N N A BIS IN S T ITUT E
WWW. AR APC . C O M/MC I
Objectives
Cannabis and the cannabinoids
The human endocannabinoid system
Cannabis research
Cannabis and pain
Cannabis and sleep
How to use cannabis
Cannabis safety
Cannabis legality
**References provided at the end
Cannabinoids and
terpenes
Synthetic cannabinoids
Purified cannabinoids
Phyto-cannabinoids
Produced by the cannabis plant – Over 100 different phyto cannabinoids discovered to date
Schedule I: Heroin, LSD, Ecstasy, Peyote, and Marijuana (and its constituents including cd-CBD)
**High risk of harm and abuse and no scientific evidence of benefit
Clinical research highly restricted
Schedule II: Hydrocodone, Cocaine, Methamphetamine, Methadone, hydromorphone (Dilaudid),
meperidine (Demerol), oxycodone (OxyContin), Fentanyl, Dexedrine, Adderall, and Ritalin
Schedule III: Tylenol with codeine, Ketamine, Anabolic steroids, Testosterone
**HHS recently recommended rescheduling marijuana to this category. DEA deciding.
Schedule IV: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, Tramadol
What has preclinical research shown?
Osteoporotic mouse given Mice given A CB2 receptor agonist JHW133 were protected
synthetic CB2 receptor agonist JWH133- against developing rheumatoid arthritis 20
Reversed osteoporosis 19
Although these and other preclinical studies have produced impressive results in animal models of disease,
it is important to acknowledge that they were performed using high doses of synthetic cannabinoid
compounds and not with plant cannabinoids per se. Therefore, these results cannot be extrapolated
to medical cannabis. However, they do point towards future research possibilities and the
prospect of pharmaceutical products that interact with the human endocannabinoid system
Cannabis pre-clinical data: Other conditions
Neuropsychiatric illness Depression*
◦ Autism, ADHD, PTSD, alcoholism, addiction
Glaucoma*
Neuroprotection
◦ Concussion and Alzheimer’s Skin Disorders
Autoimmune disease
◦ Inflammatory bowel disease, multiple sclerosis
Coronary artery disease
Cancer
Diabetes
Irritable bowel syndrome
The Endocannabinoids and Pain
Cannabinoid CB1 receptors are
found throughout the nerves,
spinal cord, and brain along the
TRPV1 pain pathway. By interacting with
CB1, and other receptors such as
TRPV1, phyto-cannabinoids such
as THC and CBD, and human
endocannabinoids such as
On/off cells Anandamide and PEA moderate
Retrograde the transmission, processing, and
signaling
perception of pain21-27
From Hillsphysiotherapy.com.au
Cannabis and Pain
Cannabinoids share mechanisms of action with many common
medications including Capsaicin, NSAIDs, Pregabalin (Lyrica),
Gabapentin (Neurontin), and Duloxetine (Cymbalta) 21-25
Cannabinoids can also enhance the effectiveness of opiates without
increasing the risk of opiate overdose28-30
Most research shows that pain is best treated with a combination
of CBD and THC as these compounds work synergistically and are
more effective together than either compound is alone
Cannabis and Pain
Inflammation also plays a primary role in causing pain
Inflammatory chemical mediators can generate pain signals and
increase perception of pain in the brain
Inflammation is driven by the immune system
Cannabinoid CB2 receptors are present throughout the immune
system and, by binding these, cannabinoids reduce
inflammation and, by extension, inflammation-mediated pain
There is no evidence that plant cannabinoids treat
autoimmune diseases in humans
Cannabis and Pain
After examining all the available data, the National Academy of
Sciences released a report in 2017 which found “substantial
and conclusive evidence” for the effectiveness of cannabis in
treating chronic pain31
Cannabinoids can help some patients reduce or eliminate the
use of potentially harmful opioids
◦ A study in 2016 showed a 64% reduction in opioid use in chronic pain
patients who were using medical cannabis32
33-34
Cannabis and Sleep
Most human research into cannabis for sleep has used THC
due to its known sedating qualities
It is thought that cannabinoids help with sleep by binding to
CB1 receptors in the brain which increase levels of a sleep-
promoting chemical called adenosine and by suppressing the
brain’s arousal system
Several human studies have shown that THC can be effective in
inducing and/or maintaining sleep
35-37
Cannabis and Sleep
One human study using synthetic THC (Dronabinol), showed
improved sleep parameters in individuals with moderate or
severe sleep apnea
Another review of human studies showed that CBD can be
effective for insomnia and REM sleep disorder
Anecdotal evidence suggests the minor cannabinoid CBN
and the terpene Myrcene can help promote sleep
How to Use Cannabis
Cannabis compounds present in the native plant
occur as acid structures which have no biologic effect
in the human body: THC-A, CBD-A, CBN-A, CBC-A,
CBG-A, etc. For the acid component to be broken off
and for the chemicals to become activated, heating is
required.
Heating is used in processing of cannabis products
and when smoking or vaporizing cannabis
How to use cannabis
Common methods of administration of cannabis include
inhalation (smoking/vaping), under the tongue (sublingual
tinctures), administered into the sides of mouth (oromucosal
spray) swallowed (edibles), transdermal through the skin
(creams and patches), or transrectal (suppositories)
In all cases, except for transdermal use, the goal is to get
cannabis compounds into the bloodstream where they can be
circulated throughout the brain and body
How to use cannabis
--In Maryland, adults 21 or older may posses up to 1.5 ounces of cannabis flower, 12 grams of
concentrated cannabis, or a total amount of cannabis products that does not exceed 750 mg THC
--In Virginia adults 21 or older can legally possess up to 1 ounce of marijuana
--In DC, adults 21 or older can legally possess up to 2 ounces of marijuana
--In Delaware, adults 21 or older can legally possess up to 1 ounce of marijuana leaf or
equivalent amounts of marijuana products in other forms.
While DC allows Maryland and Virginia medical cannabis patients go to dispensaries in the
District of Columbia, Maryland and Virginia only allow patients certified in their own states go to
their dispensaries
Cannabis Legality
In Maryland, Virginia, and Delaware, Recreational (Adult Use) cannabis has
been signed into law
In Maryland, cannabis can be purchased by anyone age 21 and older at the
same dispensaries where medical cannabis is sold. Recreational products are
fewer in number, are lower in potency, and are taxed
In Virginia and Delaware, there are currently no recreational cannabis
dispensaries
Although the District of Columbia has sought to legalize recreational cannabis,
they have been over-ruled by Congress. In DC, there is what is called “gifting” of
cannabis at brick-and-mortar stores
Unlike medical cannabis in DC, “gifted” cannabis is not regulated or tested
Medical Cannabis - Summary
Using cannabis for pain, inflammation, anxiety, or
insomnia can be complicated, and it is recommended that
an individual consult with a cannabis-literate clinician to
help with dosing and to ensure that cannabis is used
safely and effectively
Cannabis will not work for everyone all the time
The providers at the ARA Medical Cannabis Institute
stand ready to offer guidance, oversight, and support
How to learn more and schedule
https://arapc.com/mci
Call 240-621-7433
1. John McPartland and Ethan Russo, MD. Cannabis and Cannabis Extracts: Greater Than the Sum of Their
Parts? In Cannabis Therapeutics in HIV/AIDS. (Vol. 1, No. 3/4, 2001) p. 107.
2. Ibid p. 107
3. Ibid p. 108
4. Ibid pp. 107-108
5. Davis MP, Behm B, Mehta Z, Fernandez C. Am. The Potential Benefits of Palmitoylethanolamide in
Palliation: A Qualitative Systematic Review. J Hosp Palliat Care. 2019 Dec;36(12):1134-1154].
6. Cruccu G, Di Stafano G, Marchettini P, Truini A. Micronized Palmitoylethanolamide: A Post Hoc Analysis
of a Controlled Study in Patients with Low Back Pain. CNS and Neurological Disorders. 2019, 18. 491-
495.
7. Scaturro D, Asario C, et al. Combination of Rehabilitative Therapy with Ultramicronized
Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study. Pain Ther (2020) 9: 319-
326
8. Paul Clayton, Mariko Hill, Nathasha Bogoda, Silma Subah, and Ruchitha Venkatesh.
Palmitoylethanolamide: A Natural Compound for Health Management. Int J Mol Sci. 2021 May; 22(10):
5305.
9. Mark H. Kimmins, MD. Medical Cannabis in Canada. Milner and Associates 2019. P. 53.
10. John McPartland and Ethan Russo, MD. Cannabis and Cannabis Extracts: Greater Than the Sum of Their Parts? In Cannabis
Therapeutics in HIV/AIDS. (Vol. 1, No. 3/4, 2001) p. 115
11. Kimmins, p 54.
12. McPartland and Russo, p 115.
13. Kimmins, p 54.
14. McPartland and Russo, p 118.
15. Kimmis p 54.
16. McPartland and Russo, p 115
17. Kimmins, p 54.
18. McPartland and Russo, p 116
19. Bab et al. Endocannabinoids and the regulation of bone metabolism. J. Neuroendocrinol. 2008 May;20 Suppl 1:69-74.
20. Kinsey SG et al. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related
thermal hyperalgesia in mice. Pharmacol Biochem Behav. 2011 Oct; 99 (4): 718-725.
21. Costa B, et al. Vanilloid TRPV1 receptor mediates the anti-hyper analgesic effect of the non-psychoactive cannabinoid,
cannabidiol, in a rat model of acute inflammation. Br J Pharmacol. 2004 Sept; 143 (2): 247-50.
22. Vaughn CW et al. Retrograde signaling by endocannabinoids. Handb Exp Pharmacol. 2005; (168): 367-83.
23. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002.
Nov; 68 (4): 247-86.
24. Masanobu K. Control of synaptic function by endocannabinoid-mediated retrograde signaling. Proc Jpn Acad Ser B Phys Biol
Sci. 2014 Jul 31; 90(7): 235–250
25. Maione S et al. non-psychoactive cannabinoids modulate the descending pathway of antinociception in
anesthetized rates through several mechanisms of action. Br J Pharmacol (2011);162. 584-596.
26. Xiong W et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting a3 glycine receptors. J
Exp Med. Vol. 209. No. 6. 1121-1134.
27. Corchero J, et al. Delta 9-tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in
the spinal cord of the rat. Life Sci. 1997;61:L39–L43.
28. Wilson AR et al. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent
morphine antinociception. Neuropharmacology. 2008;55(7):1219–1225.
29. Cichewicz, D.L. & McCarthy, E.A. 2003. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and
opioids after oral administration. Journal of Pharmacology and Experimental Therapeutics 304 (3): 1010–15.
30. Cichewicz, D.L. & Welch, S.P. 2003. Modulation of oral morphine antinociceptive tolerance and naloxone-
precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. Journal of Pharmacology and Experimental
Therapeutics 305 (3): 812–17.
31. The Health Effects of Cannabis and Cannabinoids. The Current State of Evidence and Recommendations for
Research. National Academies of Sciences, Engineering, and Medicine; Health and Medicine
Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of
Marijuana: An Evidence Review and Research Agenda. Washington (DC): National Academies Press
(US); 2017 Jan 12.
32. Boehnke, KF, Litinas, E, Clauw, D. Medical cannabis use is associated with decreased opiate medication use in
a retrospective cross-sectional survey of patients with chronic pain. J Pain.17. 739-744 (2016).
33. Cousens, K and DiMascio A. Delta 9 THC as a hypnotic: an experimental study of three dose levels.
Psychopharmacologia 33, 355-364 (1973).
34. Kuhathasan, A, Dufort, A, MacKillop J et al. The use of cannabinoids for sleep: A critical review on clinical
trials. Exp Clin Psychopharmacol. 2019 Aug; 27 (4): 383-401.
35. Carlini, E.A and Cunha, J.M. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 21, 417-427S
(1981).
36. Ware, M.A. Fitzcharles, M.A, Joseph, L et al. The effects of nabilone on sleep in fibromyalgia: results of a
randomized controlled trial. Anesth. Analg. 110, 604-610 (2010).
37. Carley, D. W et al. Pharmacotherapy of apnea by cannabimimetic enhancement, the PACE clinical trial: effecs
of dronabinol in obstructive sleep apnea. Sleep 41.
38. Luke Murtha, Paul Sathiadoss, Jean-Paul Salameh, et al. Chest CT Findings in Marijuana Smokers. Radiology.
Vol 307, No. 1
39. Mark H. Kimmins, MD. Medical Cannabis in Canada. Milner and Associates. 2019. p. 77
40. Ibid, p. 79
41. Mirra Srinivasan, Ranim Hamouda, Baba Ambedkar, et al. The Effect of Marijuana on the Incidence and
Evolution of Male Infertility: A Systemic Review. Cureus. 2021. Dec; 13 (12).